Interview with Peter Schmidt, President, ProGenerika
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
Address: Am Klopferspitz 19
82152 Planegg-Martinsried
Tel: +49. 89. 78 79 73 10
Web: http://www.chromotek.com/home/
Chromotek GmbH, a biotech spin-off from the LMu Munich founded in 2008, aims to establish Chromobodies®, (which are highly efficient functional binding reagents for a multitude of immuno-logical and biochemical applications), as superior substitutes for conventional antibodies in areas like proteome analysis, target screening/validation, cell sorting and live cell HCA. on the basis of its technology (patent pending). The team of 5 biologists around CEO Ulrich Rothbauer develops novel analytical and preparative solutions for the biomolecular research market. It has successfully launched the GFP-trap®, the best commercially available pull-down reagent for GFP and/or GFP fusion proteins.
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
You have a wide experience in the pharmaceutical industry having worked for companies such as Amgen and Servier. What attracted you to Basilea? When I first considered moving to Basilea…
When we met Dr. Aleiotti in Italy, he said how important was Menarini´s acquisition of Berlin Chemie in the 1990s for the internationalization of the company in Eastern Europe and…
With a wide experience in other international pharmaceutical companies, what attracted you to come to Bausch&Lomb, the ophthalmology pharma company? Bausch&Lomb offered me a unique set of challenges and possibilities…
Gilead was founded in 1987 and only four years later it established itself in the German market. Since then the company has become internationally known for breakthroughs that resulted in…
See our Cookie Privacy Policy Here
